CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion AcquisitionInvestors Business Daily • 02/12/24
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay TherapeuticsBusiness Wire • 02/12/24